Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant

References

• Kleber H. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogs Clin Neurosci 2007;9:455–470.
   PubMedGoogle Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Rep 1962;10:799–812.
   Web of Science ®Google Scholar
• Carroll KM, Ball SM, Nich C, O’Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting behavioral therapies to enhance naltrexone treatment of opiod dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001;58:755–761.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse 2006;32:503–517.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O’Brien CP, Woody GE. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004;26:285–294.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Zwartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O’Brien CP, Woody GE. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006;31:319–328.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes E, Ling W, Illeperuma A, Gastfriend D, Silverman B. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo contrilled multicentre randomized trial. The Lancet 2011;337:1506–1513.
   Web of Science ®Google Scholar
• O’Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati H. Long term opioid blockade and hedonic response: Preliminary data from two open-label extension studies with extended-release naltrexone. Am J Addict 2010:20:106–112.
   PubMed Web of Science ®Google Scholar
• Mysels DJ, Cheng WY, Nunes EV, Sullivan M (2011) The association between naltrexone treatment and symptoms of depression in opioid dependent patients. Am J Drug Alcohol Abuse 37:22–26.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin V, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Slavina T, Pecoraro A, Woody GE. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry 2012;69:973–981.
   PubMed Web of Science ®Google Scholar
• Kukes VG, Ramenskaya GV, Guseinova CV, Sulimov GY. Pharmacokynetics of new Russian sustained reelase implantable naltrexone. Novye Lekarstvennye Preparaty (New Medicines) 2006;33:25–30.( in Russian).
   Google Scholar
• Mason BJ, Goodman AM, Dixon RM, Hameed MHA, Hulot T, Wesnes K, Hunter JA, Boyeson MG. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596–606.
   PubMed Web of Science ®Google Scholar
• Vereby K, Volavka J, Mult SJ, Resnick RB. Naltrexone disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;120:315–328.
   Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
   PubMed Web of Science ®Google Scholar
• Spielberger CD, Anton WD, Bedell J. In: Zuckerman M. & Spielberger C.D. (Eds.) The nature and treatment of test anxiety. Emotion and Anxiety: New concepts, methods and applications. Hillsdale, NJ: Erlbaum. 1976.
   Google Scholar
• Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extendedrelease naltrexone (XR-NTX) for opioid dependence: long term safety and effectiveness. Addiction 2013;108:628–1637.
   Web of Science ®Google Scholar
• Ferguson J, Sills T, Evans K, Kalali A. Anhedonia: is there a difference between interest and pleasure. Poster presented at the ACNP meeting. ACNP Abstract book on CD Rom, 2006.
   Google Scholar
• Chapman LJ, Chapman JP, Raulin ML. Scales for physical and social anhedonia. J Abnormal Psychol 1976;85:374–382.
   PubMed Web of Science ®Google Scholar
• Kaplan EL; Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958;53:457–481.
   Web of Science ®Google Scholar
• Mercer D., Woody G. An individual drug counseling. 2001. Warszawa: Stefan Batory Foundation (in Russian).
   Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition ( DSM-IV) Frances A, Pincus H, First MB. (Eds.). Substance Related Disorders, 1994; 175–272.
   Google Scholar
• Hatzigiakoumis DS, Martinotti G, Giannantonio M, Janiri L. Anhedonia and substance dependnece: cilinical correleates and treatment options. Front Psychiatry 2011;2:1–11. unci.
   PubMedGoogle Scholar
• Hulse GK, Hanh TTN, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psychiatry 2010;68:296–302. Unci.
   PubMed Web of Science ®Google Scholar
• Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen Ø, Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009;194:541–546.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Cacciola J, Griffith J. New data from the Addiction Severity Index: Reliability and validity in three centers. J Nerv Ment Dis 1985;173:412–423.
   PubMed Web of Science ®Google Scholar
• Navaline HA, Snider EC, Petro C, Tobin D, Metzger D, Alterman A, Woody G.E. Preparations for AIDS vaccine trials. An automated version for the risk assessment battery (RAB): enhancing the assessment of risk behaviors. AIDS Res Hum Retroviruses 1994.
   Google Scholar
• Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999;54:127–135.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J (Eds), Measuring Alcohol Consumption, Human Press. 1992.
   Google Scholar